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Background: The immunosuppressive drug mycophenolate
mofetil (MMF), with mycophenolic acid (MPA) as active metabolite,
is a nonnephrotoxic alternative to calcineurin inhibitors. Therapeutic
drug monitoring (TDM) of MPA may improve clinical benefit from
MMF therapy, especially in MMF monotherapy or with reduced
dose of a calcineurin inhibitor. Limited data are available on TDM
strategies for MPA in orthotopic liver transplantation (OLT). The
authors here describe the pharmacokinetic (PK) behavior of MPA
after OLT and developed a Bayesian limited sampling model for
monitoring MMF after OLT.
Methods: PK data were obtained from 57 stable patients, and
trapezoidal area under the curve (AUC0–12h) was calculated. The
effect of the covariates kidney function and serum albumin concen-
tration was studied. A TDM strategy was developed based on indi-
vidualized population PKs using Bayesian estimations and limited
sampling models to predict the MPA AUC.
Results: A relationship between MMF dose and MPA AUC was
found and a 8-fold apparent clearance range of MPA was observed at
the same dose level. Significant relationships of albumin concentra-
tion and creatinine clearance with MPA plasma clearance were
identified (respectively, r² = 0.12 and 0.24; P , 0.05). A model with
limited sampling at 0, 0.5, 1, 2, and 3 hours after drug administration
showed very good correlation with trapezoidal AUC0–12h with
acceptable bias and precision (r² = 0.92, mean prediction error = 1,
mean absolute prediction error = 13; P , 0.05).
Conclusions: Remarkable variability of MPA clearance in stable
OLT patients exists, which can be partially explained by the patients’
albumin serum levels and creatinine clearance. Systemic exposure in
these patients can be accurately assessed by the Bayesian limited
sampling TDM strategy.
Key Words: orthotopic liver transplantation, therapeutic drug moni-
toring, mycophenolate mofetil, mycophenolic acid, limited sampling
models
(Ther Drug Monit 2014;36:141–147)
INTRODUCTION
The immunosuppressive agent mycophenolate mofetil
(MMF) is the 2-morpholinoethyl ester of mycophenolic acid
(MPA), the active metabolite. MPA is an inosine mono-
phosphate dehydrogenase inhibitor and therefore inhibits the
de novo pathway of guanosine nucleotide synthesis and thus
the proliferative responses of T- and B-lymphocytes.1 MMF is
widely used as immunosuppressive drug after different types of
organ transplantation, including orthotopic liver transplantation
(OLT). It is often administered in combination with dose
reduction or cessation of a calcineurin inhibitor (CNI), such
as tacrolimus (TRL) or cyclosporine (CsA), to reduce
CNI-associated nephrotoxicity.2
Especially after renal and cardiac transplantation, a sig-
nificant inverse correlation exists between MPA exposure and
the risk of acute rejection.3–8 Only few studies on MPA expo-
sure were performed in OLT patients. Similar to renal trans-
plantation, patient and graft survival after OLT are acceptable
if MMF is used in combination with CNI, but a change to
MMF monotherapy after OLT can be associated with a rate
of up to 20% acute cellular rejection, which—if not treated
adequately—can lead to chronic rejection and graft loss.9 This
may be related to low exposure of MPA.2,10–12
In contrast to an initial weight-based dose regimen and
therapeutic drug monitoring (TDM) for CNIs, at present most
clinics adhere to a fixed dose of MMF, not based on any
individual patient’s characteristics like age, weight, MPA, or
creatinine clearance.13 With more experience, it became clear
that MMF has a large interpatient variability, with exposures
varying 10-fold, and intrapatient variability over time (espe-
cially in the first 6 months posttransplantation).14 MPA has
complex pharmacokinetics (PKs), and many factors can influ-
ence MPA exposure, including kidney and liver function, levels
of serum albumin, alterations in absorption, and combination
with other immunosuppressive agents.15 Recently, studies have
been performed to explore feasibility and clinical relevance of
MPA trough level monitoring during MMF therapy in solid
organ transplantation.16,17 Also several limited sampling strate-
gies have been proposed and studied, mostly in renal transplant
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patients, with often 3–5 sampling time points taken in the first
2–6 hours after dosing.18–20 Although not specifically investi-
gated, limited sampling strategies with flexible blood sampling
using population pharmacokinetic (POP-PK) models and
Bayesian estimations may be preferred over strategies with
fixed time points based on multivariate analysis, with limited
sampling formulas. Le Guellec et al21 developed a limited sam-
pling strategy based on Bayesian estimations as a tool for MPA
TDM in renal transplant patients. However, there is limited
information on TDM of MPA in liver transplant patients.7,8
This probably becomes even more relevant in CNI-free regi-
mens or after CNI dose reduction.
Therefore, the aim of this study was to describe PK of
MPA in liver transplant patients. In addition, we were aiming
at describing interpatient variability of MPA clearance to
further explore the need for TDM in these patients. We studied
factors (covariates) like albumin concentration and creatinine
clearance that could have an effect on MPA PKs. Finally,
a Bayesian TDM strategy for use in patients after liver
transplantation was developed using flexible limited sampling
models (LSMs) for MPA.
MATERIALS AND METHODS
Fifty-seven stable patients using MMF who were at least
3 months after OLT were included (median: 231 weeks; range:
49–633). Demographics are listed in Table 1 and Supplemental
Digital Content 1 (see Table, http://links.lww.com/TDM/A60).
Apart from MMF, 24 patients received tacrolimus
(6prednisone) as comedication, 20 received cyclosporine
(6prednisone), 2 received sirolimus (6prednisone), whereas
11 patients received only low-dosed glucocorticoids next
to MMF.
MMF (CellCept, Roche, Basel, Switzerland) was taken
twice daily (bid). In our clinic, MMF dosing for liver transplant
patients used to be based on fixed dose regimens. Patients
started with 500 mg bid and if allowed by absence of leuco-
and thrombocytopenia and gastrointestinal side effects, the
dose was increased to and kept at 1000 mg bid. At the time of
this study, 22 patients received 500 mg bid and 28 patients
1000 mg bid. In 7 cases, a deviant dose of 250 mg bid
(3 patients), 750 mg bid (3 patients), or 1500 mg bid (1 patient)
was given.
After informed consent, all patients visited our clinic for 1
day. Five minutes before administration of the morning dose of
MMF, blood samples were obtained for routine chemistry
(including liver enzymes, serum creatinine, and serum albumin
concentration) and MPA trough (C0) serum concentration.
Creatinine clearance (CRCL) was calculated with Cockcroft
and Gault formula. Patients were instructed to take their evening
dose the night before their visit at 10:00 PM. Further blood
samples for MPA concentration were collected at 0.5, 1, 2, 3,
and 4 hours in 31 patients and also 6 hours after administration
of the morning dose of MMF. In 3 patients, the sample at
0.5 hours was missed. From 10 patients, 2 MPA curves were
measured on different days, so in total, 67 curves were available.
The missing C12h was obtained by extrapolation from t = 0 hour
to t = 12 hours, assuming steady-state conditions.22–24
Blood was drawn using an indwelling catheter and
collected in a vacutainer containing ethylenediaminetetraacetic
acid. Plasma MPA concentrations were determined using
high performance liquid chromatography.25 Imprecision of this
method in our laboratory was 4.6%–10.1%, depending on MPA
concentration. Lower limit of quantitation was 0.2 mg/L. To
lower possible influence from meals, patients were instructed
to take only a light breakfast—tea and a biscuit—on the morning
of measuring the area under the curve (AUC), and no additional
food or drinks were allowed until the 2 hours sample (C2).
POP-PK LSMs were developed using the KINPOP
module of MW\Pharm, version 3.60 (Mediware, Groningen,
The Netherlands; www.mwpharm.nl).26 The KINPOP module
of MW/Pharm uses an iterative 2-stage Bayesian population
procedure to estimate from rich data sets of blood concentra-
tion time curves the mathematical description of compartmen-
tal PK models. An a priori model acts as a starting point to
calculate values for each patient from the available patient-
specific data and the a priori population model, leading toward
an individualized PK model, indicated as an a posteriori model.
The population model is the PK model based on many measure-
ments in many patients. A trapezoidal AUC0–12h of all 67 curves
was calculated with the trapezoidal rule using the software pack-
age MW\Pharm.
Individualized PK parameters (individualized PK model
based on Bayesian fitting, ie, post hoc values) were obtained.
AUCs (mg$h/L) based on MPA clearance on single blood
sampling time points and combinations of time points were
calculated based on the formula: AUC ¼ ðF · doseÞclearance , in which
F is bioavailability which was fixed to 1 for MMF since no
intravenous data were available.27 The dose (mg) is the morn-
ing dose of MMF and clearance (L/h) is apparent clearance
(CL/F) of MPA in the absence of information on bioavailabil-
ity. The CL/F was estimated for all patients with Bayesian
estimation at different time points and combinations of time
points (LSMs).
Statistical analysis on patient data was performed using
SPSS 19.0 for Windows (SPSS Inc, Chicago, IL). Results are
expressed as mean 6 SD and as median and range.
Calculated AUCs (with the formula AUC = dose/
clearance), dose, albumin concentration, and CRCL were com-
pared with the trapezoidal AUC0–12h with the Pearson correla-
tion coefficient. P values ,0.05 were considered statistically
significant.
The ability to describe the trapezoidal AUC0–12h of the
different methods was also investigated by calculating the pre-
diction precision and bias according to Sheiner and Beal.28 Pre-
diction bias was calculated as the mean prediction error (MPE);
that is, the mean of differences between all AUCs0–12h
TABLE 1. Patient Characteristics of Included 57 Patients
Parameter Mean SD Median Range
Age, yrs 51 12 53 18–69
Dose bid, mg 763 281 1000 250–1500
Weight, kg 79 18 77 50–123
Albumine, g/L 44 4 44 31–50
CRCL, mL/min 78 34 75 16–171
Time after OLT, wk 247 156 231 49–633
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calculated with the formula (AUCcalc) shown above




· 100%. Prediction precision was cal-
culated as the mean absolute prediction error (MAPE); that
is, the mean of the absolute differences between all calcu-





MPE and MAPE below 20% are usually considered
acceptable because the lowest possible dose adjustment of
MMF is 250 mg. Smaller values for MPE and MAPE indicate
less bias and greater precision, respectively.
RESULTS
PK Analysis
There was a linear relationship between MMF
dose and trapezoidal MPA AUC (r² = 0.16, P , 0.05;
Fig. 1). Supplemental Digital Content 2 (see Figure,
http://links.lww.com/TDM/A59) shows the individual
MPA concentration time curves for all patients. There was
a wide (8-fold) range in MPA clearances at the same dose level
(apparent clearance = CL/F = dose/AUCtrap) in the population
(500 mg bid, 8.1–62.5 L/h, and 1000 mg bid, 9.0–71.4 L/h).
Looking at possible sources of this variability in MPA clear-
ance, Figure 2 shows the significant inverse relationship
between serum albumin concentration and MPA clearance
(r² = 0.12, P , 0.05). Specifically, low albumin levels are
related to higher MPA clearance. There was also a significant
relationship between creatinine clearance and MPA clearance,
which is shown in Figure 3 (r² = 0.24, P, 0.05). The relation-
ship of MPA trough level with the trapezoidal AUC0–12h is
shown in Figure 4.
Comedication
To explore potential differences in (dose adjusted) MPA
AUC between patients with different comedication next to
MMF, all patients were divided into 3 groups (cyclosporine,
tacrolimus, and no CNIs). These nonsignificant differences are
shown in Figure 5 (analysis of variance, P = 0.247). A similar
plot could be derived from difference in apparent clearance
(data not shown). Figure 6 shows the similar relationship of
MPA trough level with dose-adjusted trapezoidal AUC0–12h for
different groups of comedication next to MMF: CsA, TRL,
without CNI (analysis of variance, P = 0.112).
Development of LSMs
An oral 2-compartment model with first-order absorp-
tion and lag time described the data adequately. Population
parameters for the group of 57 patients were calculated. The
best parameters were selected, based on the log-likelihood
value of the MW\Pharm, the correlation with trapezoidal
MPA AUC and precision and bias. The POP-PK parameters
for MMF LSMs are shown in Table 2.
Based on the individualized PK parameters, AUCs for
the LSMs based on one- and multiple-point sampling were
calculated. Correlations of these calculated AUCs with the
trapezoidal AUC0–12h including bias and precision are shown
in Table 3.
Models with single or 2 sampling points show moderate
correlation with the trapezoidal AUC, mostly in combination
with inacceptable MAPEs. Different combinations of blood
sampling time points with 3 or more sampling points show
FIGURE 1. MMF dose versus trapezoidal MPA AUC relation-
ship (r2 = 0.16, P , 0.05).
FIGURE 2. Relationship albumin concentration (g/L)—MPA
clearance (L/h) (r2 = 0.12, P , 0.05).
FIGURE 3. Relationship creatinine clearance (mL/min)—MPA
clearance (L/h) (r2 = 0.24, P , 0.05).
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good to very good correlations with the trapezoidal AUC.
Especially, the combination 0-1/2-1-2-3 hours shows a very
good correlation with the trapezoidal AUC0–12h with acceptable
bias and precision (r² = 0.92, MPE = 1, MAPE = 13, P, 0.05).
Because 10 extra curves were available, which were not
used for model building, we tested the predictability of the
trapezoidal AUC using the PK parameters from Table 2.
Although this is not a validation, because the same patients
of these extra curves were indeed included in model building,
very good correlations and MPE/MAPE were observed with
the trapezoidal AUC (Table 4).
Correlation of MPA trough levels with the trapezoidal
AUC0–12h for all patients without using any LSMs were mod-
erate, r² = 0.66 (P, 0.05), Figure 6. The correlation of trough
level (C0) with the trapezoidal AUC0–12h, with the use of
LSMs, also was moderate (r² = 0.55, P , 0.05), with a 3-fold
trapezoidal AUC difference at random C0-levels between
1 and 2 mg/L.
Comparing the results of the group including all patients
with subgroups of patients with CsA, TRL, CNI, or no CNI did
not show a clear advantage over the model with all patients in
terms of correlation with the trapezoidal AUC0–12h and MPE/
MAPE (Table 3).
DISCUSSION
We describe the PKs of MPA in liver transplant
patients. Noncompartmental PK analysis confirmed an earlier
described linear relationship between MMF dose and the area
under the concentration time curve (AUC). However, an
8-fold variability in dose-corrected systemic exposure and
therefore apparent oral clearance was also observed, illustrat-
ing a high interpatient variability in the PK of MPA. To some
extent, this variability is explained by earlier described factors
affecting MPA PK such as serum albumin and CRCL. In the
current data, there is an inverse correlation between serum
albumin and MPA clearance. Due to the absence of collection
of unbound MPA concentration data and the specific selection
of patients from this study, no definite conclusions can be
drawn regarding the relationship between serum albumin
concentration and MPA exposure. However, the relationship
we describe is in line with previous observations: recently,
lower serum albumin was related to higher free MPA and
lower total MPA in renal transplantation.29 van Hest et al30
also found that the exposure to total MPA, as determined by
MPA clearance, significantly increased with increasing renal
function, albumin level and hemoglobin, and decreasing
cyclosporin predose level. No significant difference of dose-
adjusted MPA AUC of the 3 groups of comedication existed
(cyclosporine, tacrolimus, no CNIs).
FIGURE 4. Relationship of MPA trough level with the trape-
zoidal AUC0–12h (r2 = 0.66, P , 0.05).
FIGURE 5. Patients with cyclosporine, patients with tacroli-
mus, and patients without CNIs as comedication next to MMF
and their nonsignificant difference in dose-adjusted AUC
(P = 0.247).
FIGURE 6. Relationship of MPA trough level with dose-
adjusted trapezoidal AUC0–12h for different groups of come-
dication next to MMF: CsA (Pearson R = 0.441, P = 0.05), TRL
(Pearson R = 0.799, P , 0.01), or without CNI (no CNI)
(Pearson R = 0.711, P , 0.01) (analysis of variance, P = 0.121).
TABLE 2. Population PK Parameters for MMF LSMs
Parameters Population 6
Apparent clearance, L/h per 70 kg 17.43 8.78
Volume (central), L/kg 0.27 0.42
Intercompartimental clearance, L/h per 70 kg 21.70 21.81
Volume (peripheral), L/kg 7.56 17.40
Absorption rate constant, /h 6.28 10.96
Oral bioavailability 1 Fixed
Lag time, h 0.32 0.28
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This analysis was the basis for a proposal to improve
TDM for MMF after liver transplantation: we developed
LSMs for MPA TDM in stable liver transplant patients. The
program used for Bayesian estimations is a 2-stage approach,
which is able to predict PK parameters adequately in strictly
defined populations.
Some combinations of time points showed excellent
correlation with the trapezoidal AUC0–12h with low prediction
error when using a LSM. Because these Bayesian models have
no need for fixed time points, they are very flexible and easy to
use in daily practice in the outpatient clinic, as we have shown
before for cyclosporine and tacrolimus monitoring.31,32 The
trough level with and without the model demonstrated a mod-
erate correlation with the trapezoidal AUC.
The imprecision with a trough level approach is shown
in Figures 4 and 6. This large difference in AUC at a measured
trough level (ie, 0.5 or 1.75 mg/L) is a reflection of the large
interpatient variability and this is a serious problem with
a trough level approach.
There are several reasons for introducing TDM of
MMF in daily practice. MPA levels are related to efficacy
(rejection) and safety (adverse events).3–7,33 Yau et al34
already concluded that fixed dose regimens of MMF may
not be optimal for all patients. Others also demonstrated a sig-
nificant interpatient variation in MPA PKs due to factors such
as renal function, albumin level, and (cyclosporine) comedi-
cation.30,35–38 One-third of the patients on cyclosporine
receiving fixed dose MMF immediately after renal transplan-
tation were underdosed when the AUC was calculated, and
this was related to a higher incidence of rejection.39 Further-
more, an increase of Cmax and AUC of MPA in renal trans-
plant recipients in the months after transplantation is
described.27 This may require dose adjustments.
TABLE 3. Correlations of MPA AUC Calculated With Gold Standard (Trapezoidal) AUC0–12h for Models Based on One- and












r2 MPE MAPE r2 MPE MAPE r2 MPE MAPE r2 MPE MAPE r2 MPE MAPE
cl0 0.56 9 33 0.32 21 33 0.36 18 43 0.37 11 38 0.79 4 18
cl½ 0.33 6 34 0.27 1 28 0.31 19 43 0.33 12 35 0.15 213 31
cl1 0.26 6 38 0.17 4 34 0.21 20 49 0.24 14 41 0.27 218 29
cl2 0.33 21 44 0.22 17 40 0.26 37 58 0.30 29 49 0.32 27 26
cl3 0.33 35 49 0.09 46 62 0.37 39 53 0.25 43 56 0.64 6 22
cl01 0.66 0 26 0.41 29 26 0.59 5 34 0.53 0 29 0.80 0 16
cl02 0.70 7 27 0.50 21 27 0.60 14 33 0.56 8 30 0.87 6 15
cl03 0.74 12 29 0.75 9 35 0.64 13 30 0.66 12 32 0.78 14 21
cl12 0.25 15 40 0.22 21 40 0.31 27 48 0.27 24 44 0.40 215 24
cl13 0.35 37 49 0.54 50 57 0.41 39 52 0.41 44 54 0.35 15 33
cl23 0.56 39 48 0.64 45 54 0.36 44 56 0.48 45 54 0.69 20 27
cl012 0.65 6 29 0.41 2 32 0.57 6 31 0.51 5 31 0.79 10 20
cl013 0.72 13 27 0.64 14 33 0.68 10 27 0.62 12 29 0.83 13 20
cl023 0.72 16 28 0.63 16 34 0.61 18 31 0.62 18 32 0.83 12 18
cl0½1 0.74 29 24 0.64 215 22 0.52 28 34 0.60 210 27 0.85 27 16
cl0½2 0.75 6 22 0.60 0 21 0.57 8 30 0.60 5 25 0.87 8 13
cl0½3 0.73 12 25 0.40 19 38 0.81 4 20 0.57 12 27 0.83 15 18
cl0½12 0.76 21 22 0.80 27 17 0.52 0 29 0.67 24 23 0.79 7 17
cl0½23 0.81 11 23 0.74 8 25 0.60 12 29 0.69 11 26 0.92 12 14
cl0123 0.81 3 18 0.79 7 26 0.70 3 18 0.75 3 21 0.88 4 12
cl0½123 0.92 1 13 0.94 2 15 0.86 23 14 0.89 21 14 0.92 4 8
cl0½1234 0.94 21 11 0.92 24 12 0.94 23 11 0.93 23 11 0.95 7 10
CsA, group with CsA as comedication next to MMF; CNI, group with a CNI as comedication next to MMF; no CNI, group with no CNI as comedication next to MMF; TRL,
group with TRL as comedication next to MMF.
TABLE 4. Correlations of MPA AUC Calculated With Gold
Standard (Trapezoidal) AUC0–12h for 10 Available Extra Curves
LSM r2 MPE MAPE
cl0 0.59 29 37
cl01 0.62 17 33
cl02 0.72 27 35
cl03 0.67 34 40
cl012 0.77 12 25
cl013 0.67 28 39
cl023 0.71 35 40
cl0½1 0.54 8 35
cl0½2 0.82 15 26
cl0½3 0.86 20 27
cl0½12 0.83 22 18
cl0½23 0.87 20 26
cl0123 0.78 23 32
cl0½123 0.97 12 16
cl0½1234 0.85 8 21
Ther Drug Monit  Volume 36, Number 2, April 2014 Limited Sampling Model for MPA TDM
 2014 Lippincott Williams & Wilkins 145
Calcineurin inhibitors are widely used after organ trans-
plantation. A disadvantage of these drugs is their nephrotox-
icity. MMF, in contrast to CNIs, does not cause renal damage.
Its use may allow the lowering or even discontinuation of CNI
dosing,40,41 which may lead to better kidney function in the
long term.11,42 However, CNI cessation or dose reduction with
fixed dose MMF monotherapy (or with steroids) after liver
transplantation may lead to acute or even chronic rejection in
a significant percentage of the patients.2,10–12 A solid TDM-
based dose guiding strategy for MPA may reduce these risks.
A review article from Kaplan17 concluded that the con-
tribution of TDM for MPA in the investigated studies remains
unproven and that results of large randomized controlled trials
were awaited. Another review article from Arns et al16 con-
cluded that there still was no clear support for a substantial
clinical benefit of TDM, but that MPA AUC might be more
reliable than predose (C0) MPA levels. Zicheng et al8 devel-
oped limited sampling algorithms for implementation of MPA
monitoring in liver transplantation necessitating exactly timed
blood sampling. In the roundtable meeting of van Gelder et al15
different limited sampling strategies, mostly algorithms, for
monitoring MPA were described as good estimators of
AUC0–12h with acceptable predictive performance. Le Meur
et al14 concluded in the APOMYGRE trial that therapeutic
MPA monitoring using a limited sampling strategy can reduce
the risk of treatment failure and acute rejection in renal allograft
recipients in the 12 months posttransplant, compared with fixed
dose MMF, with no increase in adverse events.
The distinction between cyclosporine and no-cyclosporine
as comedication of MMF is described in different studies.30,43–46
Cyclosporine has an influence on MPA clearance by disrupting
the enterohepatic cycle, leading to lower MPA exposure.25,47
A limitation of our study is the absence of blood sampling time
points between 6 and 12 hours after dosing MMF, exactly the
time in which the enterohepatic recirculation may occur. Due to
these missing values, we could not entirely take the enterohe-
patic cycle into account, which may mean that the MPA AUCs
in patients using cyclosporine may be slightly higher than cal-
culated in our study. Regarding the concentration before dosing
(C0-level), no significant difference between the patients with
cyclosporine and tacrolimus was found (P = 0.122). On future
validation with more patients, covariate analysis of comedica-
tion next to MMF can be taken into account. Because of pos-
sible disturbances in bile production and flow, the influence of
the enterohepatic cycle might be different in liver transplant
patients compared with renal transplant recipients.25 We
assumed that there were no such disturbances in these stable
patients more than 3 months after OLT, as supported by a similar
dose-adjusted MPA AUC for the groups with comedication with
tacrolimus and cyclosporine.
Another limitation is that the model is based on a limited
number of patients (n = 57). However, it performed well on
10 different curves from the same patients, and we are planning
to validate this model on a larger independent patient cohort.
The role of trough level monitoring in combination with
a POP-PK model needs further validation on a larger data
set. The model with sampling at 0-1/2-1-2-3 hours for the total
group of patients, showed good correlations with trapezoidal
AUC0–12h and acceptable bias and precision. To adequately
estimate the AUC0–12h data beyond a single trough level are
needed, with probably at least 4 time points. Prospective valida-
tion is needed, measuring samples over a 24-hour period of time.
In practice, monitoring with multiple time points is
feasible, as we have shown before with cyclosporine monitor-
ing after OLT.48 It only requires a simple computer program
the like of which is available in most hospital pharmacies.
No target ranges for the MPA AUC, especially for liver
transplantation patients, have been developed yet. In the scarce
literature about TDM of MPA after liver transplantation,
Tredger et al7 suggests a therapeutic range of 1–3.5 mg/L for
trough level monitoring to prevent acute rejection and to lower
adverse effects, like infection, leukopenia, and gastrointestinal
disturbances. For renal transplantation in the early posttrans-
plant period, an AUC0–12h target of 40 mg$h$L21, or a range
of 30–60 mg$h$L21, is adhered to in the presence of a CNI.15
A target AUC of 75 mg$h$L21 (range: 60–90 mg$h$L21) for
kidney transplant recipients on MMF allows safe cyclosporine
withdrawal in most patients.49 For the moment we suggest—in
the absence of sufficient data from clinical studies—to use
similar targets in liver transplantation as in renal transplantation.
CONCLUSIONS
In conclusion, with the flexible and accurate Bayesian
LSM for MMF (we propose a model with sampling times 0-1/
2-1-2-3 hours), a tool is provided for improved TDM-based
dose guiding of MMF in liver transplant patients. Its use in
combination with the suggested target ranges may allow safe
lowering or discontinuation of CNIs after OLT to improve
renal function while avoiding rejection. Prospective validation
and assessment of clinical relevance of our model are planned.
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